Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.74 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.34 |
| ▸ | CDC25B | P30305 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3568842 | 1.00 | LMNA (0.74) | LMNABLMPTPN1MEN1ALOX15 | |
| SCHEMBL28228861 | 1.00 | LMNA (0.74) | LMNABLMPTPN1MEN1ALOX15 | |
| SCHEMBL9060842 | 0.97 | LMNA (0.70) | LMNABLMPTPN1MEN1ALOX15 | |
| Squalane SCHEMBL28103427 | 0.97 | LMNA (0.70) | LMNABLMPTPN1MEN1ALOX15 | |
| SCHEMBL16167217 | 0.97 | LMNA (0.70) | LMNABLMPTPN1MEN1ALOX15 | |
| SCHEMBL4821885 | 0.97 | LMNA (0.70) | LMNABLMPTPN1MEN1ALOX15 | |
| SCHEMBL12960699 | 0.97 | LMNA (0.70) | LMNABLMPTPN1MEN1ALOX15 | |
| Squalane SCHEMBL4987345 | 0.92 | LMNA (0.78) | LMNABLMPTPN1MEN1ALOX15 | |
| SCHEMBL317789 | 0.92 | LMNA (0.68) | LMNABLMPTPN1MEN1ALOX15 | |
| SCHEMBL316503 | 0.92 | LMNA (0.68) | LMNABLMPTPN1MEN1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846903-B2 | cubic liquid crystal formulation containing an amphiphilic compound such as 1-O-(5,9,13-trimethyltetradecyl)erythritol and a drug ( excluding a lysosomal enzyme) or cosmetic embedded in the cubic liquid crystal; time release agent | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2010-12-07 | — | — | US | disclosed |
| US-20080113923-A1 | Type II Cubic Liquid Crystal Composition | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE (JP) | 2008-05-15 | — | — | US | disclosed |
| EP-1813287-A1 | TYPE II CUBIC LIQUID CRYSTAL COMPOSITION | National Institute of Advanced Industrial Science and Technology (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113923-A1 | Type II Cubic Liquid Crystal Composition | AQP1, AQP3, SCO2 | LMNA 1444/4885BLM 118/4885PTPN1 4309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.